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ABSTRACT: Site-selective chemical conjugation of synthetic molecules to proteins expands their functional and therapeutic
capacity. Current protein modification methods, based on synthetic and biochemical technologies, can achieve site selectivity, but
these techniques often require extensive sequence engineering or are restricted to the N- or C-terminus. Here we show the
computer-assisted design of sulfonyl acrylate reagents for the modification of a single lysine residue on native protein sequences.
This feature of the designed sulfonyl acrylates, together with the innate and subtle reactivity differences conferred by the unique
local microenvironment surrounding each lysine, contribute to the observed regioselectivity of the reaction. Moreover, this site
selectivity was predicted computationally, where the lysine with the lowest pKa was the kinetically favored residue at slightly basic
pH. Chemoselectivity was also observed as the reagent reacted preferentially at lysine, even in those cases when other
nucleophilic residues such as cysteine were present. The reaction is fast and proceeds using a single molar equivalent of the
sulfonyl acrylate reagent under biocompatible conditions (37 °C, pH 8.0). This technology was demonstrated by the quantitative
and irreversible modification of five different proteins including the clinically used therapeutic antibody Trastuzumab without
prior sequence engineering. Importantly, their native secondary structure and functionality is retained after the modification. This
regioselective lysine modification method allows for further bioconjugation through aza-Michael addition to the acrylate
electrophile that is generated by spontaneous elimination of methanesulfinic acid upon lysine labeling. We showed that a
protein−antibody conjugate bearing a site-specifically installed fluorophore at lysine could be used for selective imaging of
apoptotic cells and detection of Her2+ cells, respectively. This simple, robust method does not require genetic engineering and
may be generally used for accessing diverse, well-defined protein conjugates for basic biology and therapeutic studies.
■ INTRODUCTION
Site-selective chemical modification of proteins is a versatile
strategy for modulating their function and provides diverse
structures of biological and therapeutic importance.1−5 In nature,
this process occurs under rigorous enzymatic control at a specific
residue within the sequence of a protein, mostly guided by
complex and exquisitely evolved protein−protein interactions.6
Currently, combined synthetic and biochemical techniques allow
the preparation of well-defined protein conjugates bearing the
desired modification at a specific site. Site selectivity is typically
achieved by targeting highly nucleophilic cysteine residues
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genetically installed at the protein surface,7−9 uniquely reactive
amino acids at theN- orC-terminus,10−12 or noncanonical amino
acids bearing side chains with bioorthogonal reactivity.3,13 In one
example, it has been shown that the site at which the cysteine is
introduced can modulate both the efficacy of the conjugation
reaction and therapeutic efficacy of antibody−drug conjugates in
tumor-bearing mice.9 However, these methods either rely on
extensive sequence engineering or they are limited to specific
residues at either terminus of the protein. In addition, most
methods require a large excess of often-valuable reagents or
require metals or other additives that must later be removed from
the reaction mixture.14 Thus, much remains to be learned in
order to attain efficiency and selectivity comparable to that of
enzymes, particularly when multiple sites are potentially reactive
within the same native protein.
When proteins are modified through a reaction with
electrophiles, nucleophilic cysteine residues are often targeted.
Indeed both native and engineered cysteine residues are known
to react rapidly with a variety of electrophilic reagents.4,15 While
cysteine contains the most nucleophilic side chains at
physiological pH, there are some pitfalls to relying on this
residue for selective modification. For example, cysteine is
relatively rare and constitutes only 1.9% of residues in human
proteins.12,16 Furthermore, cysteine residues are often buried
within the folded protein as disulfide bonds critical for structural
integrity.15 These residues are not often accessible for
modification, and preparing protein mutants with non-native
cysteine residues can compromise folding and function.
Although there are some isolated examples of chemoselective
modification of tyrosine,17 tryptophan,18 and more recently
methionine,19 targeting naturally occurring side chains in a
chemo- and regioselective fashion remains a great and unex-
plored challenge.20
Lysine residues, in contrast to cysteine, are much more
abundant, making up 5.9% of all sites in human proteins.12,16
Lysine is generally found on the surface of proteins due to the
dominant ionic character of the side chain that enhances their
hydrosolubility. Thus, native lysine residues are more convenient
targets for protein modification than cysteine residues, as
chronicled in the long history of bioconjugation at lysine.20,21
However, a general method to label a single lysine residue over all
other lysines has been elusive. There are, however, a number of
clues in the literature that certain lysine residues can be
selectively modified, providing a starting point for developing
such a general method. For example, kinetically controlled,
regioselective lysine labeling was achieved with some success
using substoichiometric amounts of N-hydroxysuccinimide
(NHS)-ester activated avidin reagents on two proteins
(lysozyme and RNase A) bearing a low copy number of lysine
residues (Figure 1a).22 However, the requirement of sub-
stoichiometric amounts of reagent means complete conversion is
not possible, and challenges in batch-to-batch reproducibility
make this approach difficult to generalize to more complex
protein systems. In another example, Barbas and co-workers
revealed that certain lysine residues in albumin reacted more
rapidly with α,β-unsaturated sulfonamides than other lysine
residues (Figure 1b).23,24 Recently, Cravatt and co-workers
showed that sulfotetrafluorophenyl esters are selective for lysine
and, in certain cases, hyper-reactive lysine residues could be
specifically modified in a quantitative profiling of lysine reactivity
in human cell proteome.25 A number of small molecule inhibitors
have been shown to covalently target lysine residues.26 In one
example, Kelly and co-workers designed small molecules
equipped with stilbenes and showed that these systems can
selectively and covalently modify the plasma protein trans-
thyretin with preference for one of the eight lysine ε-amino
groups displayed on the protein’s surface.27 Recently, Roush,
Rader and co-workers reported the selective modification of a
catalytic lysine on an antibody using a β-lactam electrophile.28
Unfortunately, little is known about what governs lysine
selectivity and whether any of these methods could be
generalized to any given class of proteins.
Therefore, an advance in the chemical modification of lysine is
needed, specifically, an understanding of the subtle reactivity
Figure 1. Overview of methods for lysine labeling. (a) Kinetically controlled labeling of lysine on proteins using an activated ester electrophile.22 (b)
PEG-modified TAK-242, a Toll-like receptor 4 inhibitor reacts with a single lysine on human serum albumin.23 These isolated examples of site-selective
lysine modification do not proceed to completion and have been applied to a limited number of proteins. In addition, these approaches were mostly used
for the introduction of tags for a further labeling reaction (e.g., copper(I) catalyzed azide−alkyne cycloaddition). (c) This work: Hydrogen bond assisted
chemo- and regioselective modification of lysine on native proteins. The addition reaction proceeds through a H-bonded chair-like addition transition
state leading to the subsequent spontaneous elimination of methanesulfinic acid; this restores a type 2 alkene that undergoes site-specific modification
through aza-Michael addition of suitable synthetic molecules bearing an amine nucleophile.
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differences at each lysine that could guide the design of reagents
to target the most reactive lysine residue. This fundamental
understanding of lysine reactivity could also aid in the prediction
of the site of reaction for a given protein. Such predictive power
in kinetically controlled lysine labeling would offer a valuable
method for directly modifying a protein and, in principle, be
applicable to all classes of proteins in their native form.We began
this analysis by first re-examining the basis for reactivity of
nucleophilic residues on proteins. To this end, a review of the
literature indicated that solvent accessibility is often used to
rationalize site-selective amino acid labeling. However, this
parameter alone fails to correctly predict reactivity whenmultiple
residues have similarly solvent accessibility.22 On the other hand,
it has been known for a long time that the rate of reaction
between an amino group and an electrophile in water increases
rapidly as the pH of the medium approaches the pKa of the
protonated amino group. Along these lines, enzyme active sites
are often situated in unique environments that optimize the
effective pKa of catalytic groups. In nonpolar, poorly hydrated
microenvironments, the neutral form of ionizable groups is
favored and the pKa values are shifted with respect to their
normal values in water. In these nonpolar microenvironments,
cysteine residues have higher pKa’s so that the neutral and less
nucleophilic thiol (R−SH) is favored over the charged and highly
nucleophilic thiolate (R−S−). Lysine residues, in contrast, have
lower pKa’s in these nonpolar microenvironments so that the
neutral and nucleophilic amine (R−NH2) is the predominant
species, rather than the non-nucleophilic protonated amine (R−
NH3
+). Of note, the pKa of lysine can vary up to five units within
the same protein,29 depending on its local microenvironment
and the solvent accessibility, surrounding residues and protein
folding.30 Notably, pKa depression of around two units is the
basis for substrate lysine activation for E2-mediated nucleophilic
conjugation in the small ubiquitin-like modifier (SUMO)
pathway. This modulation in the lysine pKa allows catalysis to
occur at physiological pH.31 As demonstrated through both
computational and experimental mutagenesis, pKa depression
was more dependent on desolvation rather than electrostatics, a
property governed by the presence of hydrophobic residues
nearby the catalytic lysine. Similarly, the reactivity of catalytic
lysine residues in aldolases of both natural32,33 and engi-
Figure 2. Computer-assisted design of acrylate electrophile reagents for lysine modification. (a) At near physiological pH (7.5−8.0), lysine residues
compete with cysteine asMichael donors. At lower values (typically pH 5.5−6.0) lysine residues aremostly protonated and unreactive, while undermore
basic conditions (pH > 8.5) the more nucleophilic thiolate of cysteine residues usually dominate. Thus, using stoichiometric amounts of the donor at pH
7.5−8.0, the outcome of the kinetically controlled aza-Michael addition reaction will be determined by the relative reactivity of each lysine (kobs), which is
in turn determined by their intrinsic nucleophilicity (kLys−NH2) and acidity (Ka). Highly reactive reagents can be designed to amplify the intrinsic
nucleophilicity of lysine side chains for aza-Michael ligation, while their acidity is regulated by the local sequence microenvironment. As a result,
enhanced reactivities can be obtained for certain individual lysine residues, leading to high kinetic site selectivity. (b) Acrylate electrophile derivatives
1a−d used in this study and transition states (TS, activation energiesΔG‡ in kcal mol−1) calculated with PCM(H2O)/M06-2X/6-31+g(d,p) for the aza-
Michael addition of methylamine (abbreviated lysine model). Interatomic distances (in angstrom) for the forming C−N and hydrogen bonds are shown
as blue and orange dashed lines, respectively. The β′-sulfone moiety in 1c stabilizes the aza-Michael transition state through precise hydrogen bonding to
the reacting amine, providing a ten-million-fold acceleration with respect to methyl methacrylate 1b. (c) Such hydrogen bonding is much weaker with
methanethiol (model for cysteine), and thus competitive sulfa-Michael addition transition structures or stable intermediates cannot be located on the
relaxed potential energy surface (PES). The origin for this continuously uphill reaction profile with the cysteine model is the inability of the sulfone
group present in 1c to stabilize the positive charge developed at the thiol group upon nucleophilic addition. Conversely, the positive charge developed at
the amino group of the lysine model is efficiently dissipated by the sulfone in 1c, as revealed by the exothermic reaction profile; the zwitterionic enolate is
more stable than the reactants. This constitutes the basis for lysine chemoselectivity in the presence of predominantly protonated cysteines. (d)
Complete minimum-energy reaction pathway for the aza-Michael addition reaction of methylamine and sulfonyl acrylate 1c, followed by spontaneous
elimination of methanesulfinic acid. The initial addition is the rate-limiting step. Hydrogen bonding between the nucleophilic amino group and the
sulfone moiety promotes both the aza-Michael addition and the elimination of methanesulfinic acid.
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neered34,35 provenance is enhanced by virtue of a lower pKa in
the relatively hydrophobic active site.
Inspired by the ways in which enzymes increase the acidity of
specific lysine residues, we wondered whether this phenomenon
of local pKa variation could guide selective chemical modification
of a single lysine on a native protein. Furthermore, we wondered
if an electrophilic reagent could be designed so that it can be
directed to this most reactive lysine and react selectively with its
side chain under strictly kinetic control. In this way, the first
general method for regioselective lysine labeling would be
realized.
Here, we report the discovery of that reagent: a sulfonyl
acrylate that reacts selectively with the most reactive lysine in a
protein (Figure 1c). The reagent is directed to the neutral lysine
by transient hydrogen bonding between the sulfonyl group and
the ε-amino group of the side chain. By proceeding through a low
energy, H−bond assisted chairlike addition transition state, the
key N−C bond is formed. Subsequent cleavage of the sulfonyl
leaving group, which is also facilitated by hydrogen bonding to
the lysine ε-amino group, provides an additional thermodynamic
driving force. This reaction is highly regioselective, as only one
lysine was modified for all proteins examined when using a single
molar equivalent of the reagent. The chemoselectivity was also
exquisite, with the sulfonyl acrylate reacting only with the most
nucleophilic lysine.
This method was demonstrated on five different proteins
including a therapeutic antibody without prior sequencing
engineering. The simplicity and exquisite chemo- and
regioselectivity is rare in protein modification and provides
conjugates that retain their natural folding and function.
Furthermore, the modified lysine derivative may be further
functionalized through a second aza-Michael addition, since the
departure of the sulfone leaving group unmasks another
electrophile (i.e., an acrylate) that could be selectively modified
with synthetic molecules bearing a reactive amine handle. The
full reaction sequence is orthogonal to other bioconjugation
strategies such as mixed disulfide formation, enabling the
construction of modified proteins that bear two distinct
modifications at two different sites. This conjugation method
provides far-reaching opportunities to selectively tag naturally
abundant lysine, without the need of installing noncanonical
residues3,4,13 and motifs8 that can potentially compromise the
structural integrity and function of the protein.
■ RESULTS AND DISCUSSION
Computer-Assisted Design of Sulfonyl Acrylate 1c for
Lysine Modification. Site-selective reactions at solvent-
exposed cysteines are frequently performed at slightly acidic
pH (pH ≈ 6), thus preventing reaction with solvent-exposed
lysines.7,15 At slightly basic pH, on the other hand, lysines
become competitive and heterogeneous conjugation mixtures
are obtained. While bearing this very well-known observation in
mind, we wondered if there was any possibility to make lysines
outcompete cysteines in a kinetically controlled process (i.e.,
using irreversible reactions unlike thermodynamically driven
imine ligation, for instance). While solvent-inaccessible cysteine
residues in nonpolar microenvironments have higher pKa values
thus existing mostly as poorly nucleophilic thiols (water is not
available to stabilize the ionic, nucleophilic thiolate, thus
requiring a large excess of labeling reagents to be modified),
lysine with similar nonpolar surroundings have lower pKa’s (water
is not available to stabilize the cationic, non-nucleophilic
ammonium) (Figure 2a). Thus, at near-physiological pH (7.5−
8.5), some relatively solvent accessible lysine and cysteine
residues are mostly in their neutral form, presenting an
opportunity for the regio- and chemoselective modification of
these neutral and nucleophilic lysine residues. Furthermore,
using kinetic control to modify the most reactive lysine would
allow as low as a single molar equivalent of reagentan
important prospect when the cargo to be ligated to the protein is
valuable (e.g., cytotoxic drugs or fluorophores). A key step in
realizing this goal is to identif y a reagent that reinforces the intrinsic
nucleophilicity of lysine; this would allow complete aza-Michael
ligation using equimolar amounts of the reagent even at nearly
neutral pH where the fraction of neutral lysine residues is small.
As a result, highly chemo- and regioselective lysine modification
could be attained by appropriately matching the reagent-
enhanced reactivity and microenvironmentally regulated acidity
of each lysine amino group (Figure 2a).
Type 2 alkenes (i.e., α,β-conjugated carbonyls) are reactive
electrophiles able to undergo 1,4-addition with the nucleophilic
side chains of cysteine (thiols)15 and, to a lesser extent, lysine
(amines).36,37 Among these, acrylates, acrylamides, and
maleimides are commonly used as warheads for protein
modification and covalent drug attachment, mainly through
ligation at cysteine.7,15,38Water-soluble acrylamides are relatively
unreactive,39 for example in aza-Michael addition reactions at
protein interfaces,40 when compared to acrylates. The more
reactive vinylsulfonamides41,42 have recently been used to design
inhibitors of ubiquitin activating enzymes43 and kinases.44 Also,
compounds combining both the acrylic acid and sulfone
moieties, such as 2-(sulfonylmethyl)acrylic acid derivatives,
have been used for disulfide rebridging.45,46
Considering these observations and inspired by Barbas’
prescient report on selective lysine labeling with a Toll-like
receptor 4 (TLR4) inhibitor that features a cyclohexene
moiety,23 we first performed quantum mechanical calculations
of a model aza-Michael addition reaction using several acrylate
reagents (see Supporting Figure S3). In Figure 2b, we show the
activation barriers (ΔG‡) calculated for representative examples
of acrylate-based electrophiles including cyclohexene-acrylate 1a,
acrylate 1b, methyl 2-(sulfonylmethyl)acrylate 1c, and N,N-
dimethyl-2-[(methylsulfonyl)methyl]acrylamide 1d as electro-
philes. To our delight, the ΔG‡ for 1c was calculated to be only
17.5 kcal mol−1, suggesting that reactions of this type would be
quite rapid. The source of this improved reactivity is the ability of
the sulfone moiety to precisely hydrogen bond to the
nucleophilic amine in a favorable chairlike conformation,
dissipating the positive charge developed upon addition to the
alkene of the acrylate (Figure 2c). This hydrogen bond
interaction between the lysine model and the sulfone lowers
the energy barrier by 10−16 kcal mol−1 with respect to acrylate
1b and cyclohexene-acrylate 1a. This corresponds to a 107- and
1011-fold acceleration, respectively, a rate enhancement com-
parable to that of proficient enzymes.47 TheN,N-dimethyl amide
group in 1d severely distorts and deactivates this reagent with
respect to 1c, despite featuring similar hydrogen bonding to the
incoming amine (Supporting Figure S4). Importantly, this type
of hydrogen bond activation is not possible with the cysteine
side-chain thiol due to the less polar character of the S−H bond,
providing a means to selectively modify lysine even in the
presence of free cysteine residues at near neutral pH (Figure 2c).
The subsequent elimination of methanesulfinic acid from the
zwitterionic enolate formed upon aza-Michael addition (remi-
niscent of the elimination in an E1cB mechanism) was calculated
to be spontaneous (ΔG‡ ≈ 4 kcal mol−1) (Figure 2d).
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Lysine Regioselective Modification on Albumin Using
Computationally Designed Sulfonyl Acrylate 1c. At the
outset of our studies we envisioned that the innate and subtle
differences in the reactivity of each ε-amino side chain could
enable regioselective modification of a single lysine residue on
proteins. At the same time, the ability of the ε-amino group of
lysine to hydrogen bond with the sulfone of acrylate 1c opened
the exciting prospect of using this designed reagent to favor
reaction with lysine over cysteine. To verify this hypothesis in a
protein context, we evaluated the reaction of the four
electrophiles 1a−d with a physiologially and therapeutically
relevant protein, human serum albumin (HSA). HSA is the most
abundant protein found in plasma, and recombinant HSA
(rHSA) derivatives have become available and gained wide
acceptance as bespoke proteins for formulation, drug delivery,
and imaging applications.48,49 Its native sequence features 59
lysine residues, and 35 cysteines, of which 34 are found in the
form of disulfide and one, at position 34, exists in the thiol
oxidation state. Thus, a recombinant HSA (rHSA, Recombumin
from Albumedix) provides an ideal substrate to test the potential
chemo- (lysine versus cysteine) and regioselectivity (single lysine
Figure 3. HSA lysine regioselective bioconjugation with sulfonyl acrylate reagent 1c. (a) Scheme for the bioconjugation reaction between rHSA and
sulfonyl acrylate 1c. General reaction conditions: rHSA was reacted with 1c (1 mol equiv) in TrisHCl (20 mM, pH 8.0) at 37 °C for 1 h. (b)
Optimization of reaction conditions with respect to buffer and pH (see also Supporting Table 3). (c,d) Total ion chromatogram, combined ion series,
and deconvoluted mass spectrum reconstructed from the ion series using the MaxEnt algorithm before (c) and after (d) the reaction. The region
containing all protein is marked with a left right arrow. After the reaction, protein conjugates were purified using size-exclusion chromatography and the
concentration of the starting protein and of the purified protein was measured by Bradford protein assay. Complete conversion to the desired rHSA−1c
conjugate was observed in >95% yield. (e) MS/MS spectrum of the m/z 712.93 doubly charged ion of the lysine modified peptide
GKKLVAASQAALGL from HSA. Modified residue underlined. (f) CD of rHSA and rHSA−1c. (g) Reaction of rHSA−1c with thiol specific Ellman’s
reagent shows full conversion of cysteine 34 to the corresponding disulfide. Deconvoluted mass spectrum of rHSA−1c−Ellman’s.
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modification versus multiple lysine modifications) of our
proposed method.
We started by investigating the reaction of acrylate derivatives
1a−d with rHSA. When a mere 1 mol equiv of methyl 2-
(sulfonylmethyl)acrylate derivative 1c is reacted with rHSA at
low concentration (10 μM) for 1 h at 37 °C and pH 8.0 (Figure
3a,b), a single modif ication was produced in >95% as assessed by
Liquid Chromatography−Mass Spectrometry (LC−MS) (Fig-
ure 3c,d). The difference in mass from rHSA to rHSA−1c
corresponded to Michael addition followed by E1Cb-type
elimination of HSO2Me from the enolate intermediate (Figure
2d). Importantly, our computational data were corroborated
experimentally, as electrophiles 1a, 1b, and 1d did not react with
rHSA under the same reaction conditions (Supporting Figures
S17, 18, 24). The proposed structure was consistent with
reactions on a peptide model using the electrophile 1c
(Supporting Figure 8).
Next, the product of the reaction was then subjected to
enzymatic digestion followed by LC−MS/MS analysis of the
resulting peptides. We found that the modification occurred in
the peptide GKKLVAASQAALGL (modified residue under-
scored and in bold−total of 91% sequence coverage) as observed
in the MS/MS spectrum, which corresponds to lysine 573
(Figure 3e). Lysine 573 was the only residue modified by reagent
1c, indicating a high degree of regioselectivity for the reaction.
Additionally, circular dichroism (CD) analysis of rHSA and
rHSA−1c showed no alterations in secondary structural content
(Figure 3f), which reflects the mildness and efficiency of the
conjugation process. Finally, and to demonstrate the chemo-
selectivity of the reaction for lysine over cysteine, we then
incubated the product of the reaction of rHSA with 1c with thiol
specific Ellman’s reagent. We observed rapid and complete
conversion to the corresponding disulfide product rHSA−1c−
Ellmans’ (Figure 3g), indicating that cysteine was not modified
when the protein was treated with acrylate 1c in the first step.
The same doubly modified protein could also be obtained when
performing the reactions in reverse order (Supporting Figure
27).
Lysine 573 is known to play a key role in albumin’s binding to
the FcRn receptor.50 Using Surface Plasma Resonance (SPR), we
confirmed that modification of lysine 573 using the sulfonyl
acrylate reagent 1c leads to a 2-fold reduction in FcRn affinity as
expected (Table 1 and Supporting Figure 33). Next, we applied
the same reaction conditions to an rHSA mutant featuring a
proline residue at position 573, rHSA-K573P, which is known to
increase FcRn binding affinity, in order to evaluate the
regioselectivity of our lysine modification protocol (Figure 4a).
We were pleased to observe the formation of a chemically
defined conjugate after reaction of rHSA-K573P with 1c for 1 h
at 37 °C as determined by LC−MS (Figure 4b). Tryptic
digestion followed by LC−MS/MS of the resulting peptides
indicated modification of lysine at position 4 (Figure 4c).
Reaction of 1c at position 4 resulted in a conjugate that retained
both secondary structural content (Figure 4d) and binding
efficiency to FcRn (Table 1 and Figure 4e). These data
demonstrate the regioselectivity of the reaction, since when the
modified lysine in the native sequence is genetically altered, the
reaction occurs predominantly at the next most-reactive lysine
site as exemplified here for rHSA.
Our data indicate that when 1c and rHSA react at an equimolar
ratio, the reaction proceeds with complete chemo- and
regioselectivity after 1 h at 37 °C. Phosphate or TrisHCl buffers
at near pH 8.0 were optimal for the lysine modification (Figure
3b, Supporting Table 3 and Supporting Figures 22, 23). As a
direct comparison, when an NHS ester derivative is used under
the same equimolar reaction conditions for 1 h at 37 °C,
incomplete conversion and the formation of conjugates with one
and two modified residues were detected by LC−MS
(Supporting Figure 35). Complete consumption of the rHSA
protein could only be obtained using 10 equiv of the reagent
which led to a heterogeneous mixture varying between three to
eight modifications (Supporting Figure 36). These experiments
show both the superior reactivity and selectivity of the sulfonyl
acrylate 1c when compared with conventional NHS ester
reagents. We noticed that the reaction also occurs at pH 7.0,
though conversion is lower (∼40%) due to an increased
protonation of lysine 573. The fact that the modification occurs
at all at pH 7.0 reflects the capacity of 1c to augment the intrinsic
reactivity of lysine residues toward aza-Michael ligation (large
kLys‑NH2 in Figure 2a), the local pKa modulation of a specific
lysine, and the inability of cysteine residues to react under our
optimized conditions. While we note that such chemoselectivity
will have to be evaluated for each protein on a case-by-case basis
(especially for enzymes containing highly reactive cysteine
residues such as cysteine proteases, glutathione transferases, and
some oxidoreductases), the results in Figure 3 demonstrate that
chemo- and regioselective modification of lysine in the presence
of a cysteine is possible at least in certain cases. Additionally, the
use of 1 mol equiv is critical. When using excess 1c (10 and 50
mol equiv), additional conjugations are observed (Supporting
Figures 20, 21). As expected for a kinetically controlled ligation, it
is therefore critical to take care in measuring both protein
concentration and the concentration of 1c so that nomore than 1
mol equiv is present in the reaction.
This new site-selective reaction is operationally simple and
high yielding (the isolated yield of the modified protein was 98%
as assessed by Bradford assay). Furthermore, the conjugate
rHSA−1c remained stable in both human plasma and in the
presence of biological thiols such as glutathione, an important
feature for a potentially useful ligation for the preparation of
therapeutic conjugates (Supporting Figures 25, 26).
Scope of Modification on Native Proteins. Encouraged
by the exquisite selectivity observed on rHSA, we next explored
the reaction of 1c with other proteins. Biologically and medically
relevant proteins were selected: lysozyme, an endogenously
produced glycoside hydrolase that is immunologically important
and provides defense against bacteria by damaging their cell
walls;51 the C2A domain of Synaptotagmin-I (C2Am)52 and
Table 1. Kinetic Analysis at pH 5.5 of rHSA Derivatives
Binding to Human FcRn Receptor
Albumina kon (10
−3/ms) koff (10
3/s) kD (μM)
rHSA 3.92 63.3 16.13
rHSA−1c 2.15 62.5 29.10
rHSA-K573P 9.75 4.88 0.501
rHSA-K573P−1c 7.92 4.65 0.587
aValues are mean of duplicates. There are differences observed in
FcRn binding kinetics between the albumins. For rHSA/rHSA−1c:
FcRn binding is negatively impacted when 1c was installed at position
573. The kon for rHSA−1c is much slower, driving the kD value up to
29.1 μM, which is 2-fold less than rHSA; for rHSA-K573P/rHSA-
K573P−1c: The kon when position 4 is modified is slightly slower
(7.925) compared to nonmodified rHSA-K573P (9.755), pushing the
affinity kD for the human FcRn up slightly.
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Annexin V,53 both biomarkers used to image apoptotic tissues in
patients; and a full IgG antibody, Trastuzumab, which constitutes
a frontline treatment to treat breast cancer patients.54 These
proteins allowed us to test not only the regioselectivity of the
reaction on diverse protein scaffolds but also the chemo-
selectivity as C2Am and Annexin V have a free cysteine residue
that could potentially react with the sulfonyl acrylate 1c.
Markedly, under essentially identical conditions to those used
on rHSA (low protein concentration, 1 equiv of sulfonyl acrylate
1c, 1−2 h at 37 °C and pH 8.0), a single modif ication was observed
for all proteins studied (Figure 5a). LC−MS analyses indicated in
all cases the addition of 99 Da corresponding to the aza-Michael
reaction of a lysine with the alkene of the acrylate followed by
spontaneous elimination of the methanesulfonyl group (Figure
5b−e). Moreover, in the case of proteins having free cysteine
residues (C2Am and Annexin V) the reactive sulfhydryl side
chain remained unreacted and could be subsequently modified
through mixed disulfide formation after reaction with the thiol-
specific Ellman’s reagent (Supporting Figures 41, 42, 46, 47). For
these proteins, cysteine could be also modified first with Ellman’s
reagent and then further conjugated through lysine with 1c.
These data not only suggest preferential selectivity of lysine for
reaction with the sulfonyl acrylate 1c at pH 8.0 but also show that
our new method may be used to obtain dually modified proteins
at specific cysteine and lysine residues. Again, we note that this
chemoselectivity needs to be established in cases where catalytic
cysteine residues might compete for modification, but the C2Am
and Annexin V experiments are two additional examples where a
lysine can be selectively modified in the presence of cysteine.
Next, we assessed antigen binding of the modified
Trastuzumab−1c using biolayer interferometry (BLI) and
confirmed that the introduction of a single lysine modification
within the light chain of the antibody (Figure 5e) did not affect its
ability to recognize the Her2 antigen it was designed to bind to
(KD = 16± 2.2 nM for Trastuzumab comparedKD = 14± 1.4 nM
of Trastuzumab−1c) (Figure 5f). Finally, we tested the stability
of Annexin V−1c both in the presence of 1 mM of reduced
glutathione and in human plasma at 37 °C. Importantly, the
conjugate remained stable under those conditions for up to 48 h
(Supporting Figures 39, 40), which demonstrates the potential
utility of our method to create stable conjugates for therapeutic
applications. This is a distinct advantage over more traditional
conjugation methods such as disulfide formation or maleimide
conjugates that are not stable in the presence of thiols.7,55
Moreover, the optimized ligation method is advantageous in at
least two additional ways. First, the reaction is highly chemo-
selective with exclusive reaction at lysine and no side reactions at
cysteine. Second, the conjugation method does not require prior
sequence engineering and is applicable to proteins in their native
constitution. This is critically important for proteins such as
Figure 4. Sequence-lysine conjugation effect of albumins on their binding affinity to human FcRn receptor. (a) Scheme for the bioconjugation reaction
between mutant rHSA-K573P and sulfonyl acrylate 1c. General reaction conditions: rHSA-K573P was reacted with 1c (1 mol equiv) in TrisHCl (20
mM, pH 8.0) at 37 °C for 1 h. (b) Mass spectrometry characterization of lysine conjugation with 1c. ESI−MS spectra of rHSA-K573P (i) before (red)
and (ii) after (gray) conjugation with 1c. (c) MS/MS spectrum of the m/z 416.54 triply charged ion of the lysine modified N-terminal peptide (1−10)
DAHKSEVAHR. Modified residue underlined. (f) CD of rHSA-K573P and rHSA-K573P−1c. (d) CD analysis of the nonmodified rHSA-K573P and
the conjugate rHSA-K573P−1c. (e) SPR comparison of the binding to human FcRn of rHSA-K573P and rHSA-K573P−1c.
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antibodies where mutating the sequence to install a uniquely
reactive group can compromise their binding affinity. Our
modification of the antibody Trastuzumab demonstrates that the
protein can be modified directly and retain its full activity.
Theoretical Prediction and Experimental Validation of
Modification Site. Based on the hypothesis that the most
acidic, reagent-accessible lysine residues would be highly reactive
with sulfonyl acrylate 1c, we estimated the lysine pKa of three of
the proteins we studied using constant pH molecular dynamics
simulations (CpHMD, see Supporting Information). Accurate
protein pKa prediction remains a great challenge for computa-
tional chemistry,56 and among the many available methods,
CpHMD57,58 is perhaps the most successful one since it takes
both solvation and protein dynamics into consideration, albeit at
a high computational cost.56
Lysozyme has six potentially reactive lysine residues and no
cysteine. Based on our calculations, one of these lysines, K33, has
a significantly lower pKa (9.5) than the other Lys (pKa≈ 10) due
to its hydrophobic microenvironment imparted by the
surrounding residues F34, F38, and W123 (highlighted in
orange in Figure 6a). Other methods such as Multi-
Conformation Continuum Electrostatics (MCCE)59 predicted
an even lower pKa for K33 of 8.1 versus 10−11 for the other
lysines. Furthermore, the X-ray structure of hen egg white
lysozyme (PDB ID 1G7H) shows a hydrogen bond between the
N of K33 and the NH2 group of N37, suggesting that the side
chain of K33 is actually deprotonated (i.e., neutral, reactive form,
see Supporting Figure 5). Consistent with this computational
prediction, enzymatic digestion of the modified lysozyme with 1c
followed by LC−MS/MS analysis the resulting peptides (35%
sequence coverage that covers all 6 lysine residues) confirmed
that lysine 33 is in fact the only modified residue in lysozyme
(Figure 6a). Furthermore, and although the simultaneous
prediction of the pKa of all 59 lysines in rHSA through
CpHMD simulations is computationally very demanding, we
were able to calculate the pKa of selected lysine residues such as
lysine 64 (targeted by TAK-242;23 pKa 11.07), lysine 573
(targeted by 1c; pKa 10.39), and lysine 574 (adjacent to Lys573;
pKa 10.89) (Supporting Table 2). The 0.5−0.7 pKa units
difference between these lysine residues agrees well with the
observed site selectivity achieved by sulfonyl acrylate 1c toward
lysine 573 in rHSA and reinforces the important role of lysine
acid−base properties in selective labeling.
The same phenomenon was observed for C2Am in which
K100 shows the lowest calculated pKa (10.1) among the 13
surface-exposed lysines (Figure 6b). As in lysozyme, K100 is
located in a small hydrophobic patch (L63-P65-G99-L97-V92).
The calculated pKa of the engineered C95, which has been shown
to be reactive under physiological conditions,7 is 10.3, suggesting
a possible competition between both residues. However, LC−
MS/MS analysis after enzymatic digestion (95% sequence
coverage) of the protein conjugated with 1 equiv of 1c (Figure
Figure 5. Regioselective lysine modification is applicable to a wide-range of native protein scaffolds. (a) Optimized conditions to modify a single lysine
on multiple native proteins. (b−d) ESI−MS spectra for three modified proteins showing a homogeneous product for each bioconjugation. Combined
ion series and full ESI−MS spectra can be found in the Supporting Information. (e) ESI−MS spectra before (red) and after (blue) conjugation of 1c to
the full-length IgG antibody Trastuzumab. The addition of 99 Da occurred exclusively in the light chain of the antibody. (f) Biolayer Interferometry
(BLI) curves (in blue) and fitting curves (in red) obtained for Trastuzumab−1c. For the curves of nonmodified, commercial Trastuzumab, see
Supporting Figure 60. −− indicates disulfide bonds in Trastuzumab.
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6b) showed selectivity for K100. This result highlights how
selective reaction at lysine instead of cysteine can be reinforced
by the predicted H-bond interaction in the aza-Michael addition
transition state between 1c and primary amines (Figure 2).
Additionally, cysteine 95 could be specifically modified after
reaction of C2Am with 1c using thiol specific Ellman’s reagent
(Supporting Figures 46, 47). In the case of Annexin V, all 22
lysine residues are relatively solvent accessible and thus have
calculated pKa’s in the 10−11 range, with K57, K300, and K308
showing slightly depressed pKa’s (Figure 6c). Enzymatic
digestion of Annexin V−1c followed by LC−MS/MS analysis
gave only 59% sequence coverage and indicated lysine K300 as
the one modified (Figure 6c). This result is in line with the
theoretical calculations despite the smaller differences in the
calculated pKa’s and low sequence coverage. In addition, Annexin
V features a cysteine residue at position 315 which is deeply
buried in a hydrophobic region of the protein; the pKa of this
buried cysteine was calculated to be >14, suggesting very low
reactivity at near physiological pH. Indeed, C315 has been shown
to react with other alkenes only when a very large excess (1000 to
10000 equiv) is used.60 As in the case of C2Am, the free C315 in
Annexin V could also be modified to full conversion upon
reaction with thiol specific Ellman’s reagent indicating that this
cysteine does not react with 1c under the standard conditions
(Supporting Figures 41, 42).
The site-selective, differential labeling of lysine and cysteine in
the same protein is uncommon. In fact, we are aware of only one
other example where lysine has been modified regioselectively in
the presence of cysteine, and Barbas’ report was limited to a
single protein.23 The examples of site-selective lysine mod-
ification in the presence of reduced cysteine residues illustrated
above are novel in the general capability and rational
Figure 6. Theoretical calculation of the most reactive lysine residue on three proteins and obtained MS/MS spectra confirming the modified site. The
pKa values for lysine and cysteine residues in (a) lysozyme, (b) synaptotagmin C2Am domain, and (c) Annexin V were estimated through constant pH
Molecular Dynamics simulations (CpHMD); deeply buried cysteine residues such as C315 in Annexin V could not be fully titrated in the pH 5−14
range; terminal residues cannot be evaluated through the CpHMD method (pKa value not calculated). These values are mapped onto surface
representations for each protein (lysine and cysteine highlighted in blue and yellow, respectively). The lowest pKa lysine for each protein is highlighted in
red; in agreement with these predictions, the lowest pKa lysine residues are the ones selectively modified as found through enzymatic digestion followed
by LC−MS/MS analysis (modified residues underlined). Hydrophobic residues around the reactive lysines (shown in orange) contribute to lower their
pKa.
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predictability of the site of modification. The unique architecture
of the sulfonyl acrylate derivative 1c enables this improvements
through its highly selective recognition of themost reactive lysine
residues (i.e., those with lower pKa’s) through precise hydrogen
bonding in the aza-Michael addition transition state.
Precise Protein Labeling for Bioimaging. The sponta-
neous elimination of methanesulfinic acid after reaction of 1c
with a lysine on a protein restores a type 2 alkene that may, in
principle, serve as a handle for further attachment of various
cargoes such as polyethylene glycol (PEG) polymers, fluoro-
phores, or drugs. In particular, we considered that synthetic
molecules bearing a nucleophilic amine would provide a suitable
nucleophile for aza-Michael addition ligation since acrylates are
good Michael acceptors for amines. Importantly, such a reaction,
and unlike thiol-based Michael addition, would be fully
compatible with disulfide bonds and free cysteine residues on
proteins thus enabling a noninvasive second-stage chemo-
selective ligation.
To test this hypothesis, we first examined the aza-Michael
addition of benzylamine and a PEG3NH2 polymer, of which the
latter is present in many commercially available dyes and drugs.
We found that both amines could be successfully conjugated after
1 h of reaction at room temperature with alkene-tagged protein
Annexin V−1c, as assessed by LC−MS (Supporting Figures 43,
44). These results demonstrate that the activated alkene
generated upon site-selective reaction of the sulfonyl acrylate
1c with a lysine residue may be used to further append synthetic
molecules to proteins through a second aza-Michael ligation
using low quantities of amine reagents (1 mM of reagent for a 10
μM protein concentration).
Next, we decided to demonstrate the utility of our method to
produce fluorescently labeled proteins for bioimaging.5 As a
model protein, we chose C2Am as it has been validated in vivo for
detecting apoptotic tissue, using a variety of methods including
magnetic resonance imaging (MRI)61 and single photon
emission computed tomography (SPECT).62 C2Am−1c,
which displays the acrylate moiety, reacted rapidly over 1 h
with 1 mM of the commercially available PEGylated fluorophore
FITC-PEG3NH2 to afford a precisely labeled fluorescent
conjugate, C2Am−1c−FITC, as detected by SDS-PAGE (Figure
7a, b). We then tested if this C2Am derivative retains its inherent
functionality of binding to the phosphatidylserine (PS)
phospholipid on the surface of apoptotic cells.52 The use of
C2Am−1c−FITC allowed ready visualization of HEK293 cells
rendered apoptotic by treatment with actinomycin D (Figure
7c). Blocking studies where treated cells were first incubated with
nonlabeled C2Am and then with the fluorescent surrogate
C2Am−1c−FITC showed a significant decrease of the mean
fluorescence intensities (MFI). This control experiment verified
that the specific affinity of C2Am−1c−FITC for apoptotic cells is
retained after functionalization with the fluorophore (Figure 7d).
Colocalization of C2Am−1c−FITC with the membrane
Figure 7. Site-selective fluorescence labeling of the lysine−acrylate 1c derivative through aza-Michael ligation: application for the selective imaging and
detection of apoptotic positive cells. (a) Scheme for the site-selective labeling of C2Am−1c with commercially available FITC−PEG3NH2. General
reaction conditions: C2Am−1c was reacted with FITC−PEG3NH2 (100 mol equiv) in TrisHCl (20 mM, pH 8.0) at room temperature for 1 h. (b)
Treatment of C2Am−1c with FITC−PEG3NH2 gave a single new fluorescent band as detected by SDS-PAGE that is consistent with site-selective
incorporation of FITC. Lanes 1 and 2, Coomassie staining. Lanes 3 and 4, fluorescence. (c) Epifluorescence images of nonapoptotic (control) and
apoptotic HEK293 cells after labeling with C2Am−1c−FITC. Blocking studies were performed by preincubating apoptotic cells with a 10× excess of
nonfluorescent C2Am before incubation with C2Am−1c−FITC. (d) Themean fluorescent intensity (M.F.I.) of apoptotic cells incubated with C2Am−
1c−FITC (black bar) or blocked with nonfluorescent C2Am before incubation with C2Am−1c−FITC (gray bar). (e) Confocal images of apoptotic
cells treated with C2Am−1c−FITC. Zoom in and Z-stacking showing staining of the cellular membrane. Membranes of apoptotic cells are shown in
green, while the nuclei in blue. S.D., standard deviation; a.u., arbitrary units; FITC, fluorescein isothiocyanate; PEG, polyethylene glycol.
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confirms the high specificity of the probe for the externalized PS
phospholipid, as verified by confocal microscopy (Figure 7e).
The combined advantages of chemoselectivity and efficiency
allow precise labeling of wild-type sequences without perturbing
protein secondary structure, as assessed by CD (Supporting
Figure 49) and localization (detection of apoptotic cells). In
addition, the fluorescence of the synthetic probe is fully retained
after conjugation to the protein. This simple method increases
the current repertoire for fluorescent protein labeling for
bioimaging while avoiding some of the limitations usually
Figure 8. Site-specific aza-Michael installation of FITC−PEG3NH2 and the anticancer drug crizotinib into Trastuzumab−1c preserves Her2 binding
affinity and the capacity to selectively detect Her2 positive cells. (a) Scheme for the site-specific labeling of Trastuzumab−1cwith commercially available
FITC−PEG3NH2. General reaction conditions: Trastuzumab−1c was reacted with FITC−PEG3NH2 (100 mol equiv) in TrisHCl (20 mM, pH 8.0) at
room temperature for 1 h. (b) Treatment of Trastuzumab−1cwith FITC−PEG3NH2 afforded a new fluorescent band as detected by SDS-PAGE that is
consistent with site-selective incorporation of FITC within the light chain of Trastuzumab. Lanes 1−2, Coomassie staining. Lanes 3−4, fluorescence.
From the bottom to the top: a band around 20−25 kDa (light chain); a band around 50 kDa (heavy chain). (c, d) Analysis of specificity of
Trastuzumab−1c−FITC toward Her2 by flow cytometry. (c) Superposition of contour plots of side-scatter detection versus FITC-equivalent
fluorescence intensity, in HepG2 cells (blue, expressing low levels of Her2/c-erb-2), and in SKBR3 cells (red, expressing high levels of Her2/c-erb-2).
Controls were treated with nonconjugated Trastuzumab while samples were treated with increasing concentrations of Trastuzumab−1c−FITC (10, 50,
and 150 nM). (d) Percentage of FITC-positive single cells, after treatment with fluorescently labeled or nonlabeled Trastuzumab, in both HepG2 cells
(blue) and SKBR3 cells (orange). (e) Scheme for the site-specific conjugation of crizotinib to Trastuzumab−1c. General reaction conditions:
Trastuzumab−1c (10 μM) was reacted with crizotinib (10 mM, 1000 mol equiv) in TrisHCl (20 mM, pH 8.0) at room temperature for 2 h. (f) Mass
spectrometry characterization of site-specific drug conjugation. ESI−MS spectra of the light chain (i) before (red) and (ii) after (gray) conjugation of the
anticancer drug crizotinib to Trastuzumab−1c. Calculated mass for the light chain of Trastuzumab−1c−crizotinib, 23986 Da. (g) KD constant derived
from BLI experiments for Trastuzumab−1c−crizotinib. For the BLI curves obtained with the Her2 receptor see Supporting Figure 61. (h) CD of
Trastuzumab and Trastuzumab−1c−crizotinib. (i, j) HEK293T cells (expressing low levels of Her2/c-erb-2) and SKBR3 cells (expressing high levels of
Her2/c-erb-2) were incubated with 10 μM of Trastuzumab−1c−crizotinib and analyzed by flow cytometry.
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associated with these processes such as fluorescence quenching
or compromised protein activity and localization.
Regioselective Antibody Conjugation. The ability to
precisely conjugate fluorophores and cytotoxic drugs to
antibodies is essential in modern biomedical technology.63
Methods to label antibodies usually rely on the modification of
interchain disulfides, genetically encoded free cysteine residues,
or noncanonical amino acids.64 Though these methods have
been adapted with some success, there are currently several
limitations. For instance, modification of the cysteine residues
after disulfide reduction is difficult and often leads to
heterogeneous mixtures.65 In cases where a free cysteine is
genetically installed in antibodies or when a noncanonical is
engineered into the protein, there is the risk that altering the
native sequence of the antibody can lead to significant loss of
binding affinity to the target antigen.8 In contrast, our method
can be applied directly to a therapeutic antibody in its native
form, without the need for genetic engineering that could
compromise its activity. To demonstrate the utility of our
regioselective lysine methodology in preparing homogeneous
antibody conjugates, we decided to react Trastuzumab−1c with
an amine-containing fluorophore (Figure 8a). Much to our
delight, the reaction proceeded to completion in the presence of
1 mM of FITC-PEG3NH2 after 1 h at room temperature
resulting in a well-defined, fluorescently labeled antibody
conjugate (Figure 8b). Importantly, the fluorescent Trastuzu-
mab−1c−FITC conjugate still retained its specificity toward its
target antigen (Her2/c-erb-2), as demonstrated by flow
cytometry. This experiment allowed the detection of SKBR3
cells (red) that express high levels of Her2-receptors in contrast
with cells expressing low levels of this receptor (HepG2 cells,
blue) (Figure 8c, d). Our data also indicate that the site-
specifically labeled fluorescent antibody we generated preserves
its functionality at a concentration range identical to that of its
unmodified counterpart.66 The retention of binding activity of
the antibody conjugate is a direct result of the mild and direct
lysine conjugation method. In contrast to the vast majority of
other antibody modification techniques, this method modifies
native residues with excellent chemo- and regioselectivity and
does not require sequence alteration that can lower binding
affinity and specificity toward the target antigen.
We have further validated our protocol for the construction of
stable and functional antibody conjugates through the
conjugation of the anticancer drug crizotinib to the acrylate
present in Trastuzumab−1c. Crizotinib is an approved kinase
inhibitor for the treatment of ALK-rearranged nonsmall-cell lung
carcinoma (NSCLC).67 This drug features a reactive piperidine
motif that has been shown to undergo aza-Michael addition to
dehydroalanine-tagged proteins.68 When Trastuzumab−1c (10
μM) was treated with an excess (10 mM, 1000 equiv) of
crizotinib, complete conversion to an homogeneous conjugate
with a single modification within the light chain was observed
using LC−MS (Figure 8e,f). No modifications were detected in
the heavy chain of the antibody (Supporting Figures 57 and 58).
Constant pH molecular simulations (CpHMD) for antibody
Trastuzumab (PDB id: 1n8z) showed the lowest pKa value
obtained for lysine at position 207 in the light chain, indicating
that this residue is likely the one where 1c is preferentially
installed (see Supporting Table 2). In addition, and while
hydrolysis of the methyl ester was detected under conditions
used to modify a cysteine using Ellman’s reagent, in both
examples of aza-Michael addition to Trastuzumab−1c the
methyl ester remained intact during the two-step antibody
conjugation process. Importantly, the conjugate Trastuzumab−
1c−crizotinib fully retained antigen binding properties and
secondary structural content as determined by BLI and CD,
respectively (Figure 8g, h). We also show by flow cytometry
analysis and by staining cells with an antihuman IgG Alexa-647
secondary antibody that Trastuzumab−1c−crizotinib retains its
specificity toward SKBR3 cells, which express high levels of the
Her2 antigen (Figure 8i), as opposed to HEK293 cells, which
express low levels of the target antigen (Figure 8j). These data
corroborate the mildness and selectivity of the strategy we
developed for the construction of stable and functional protein
conjugates modified at lysine. As part of our program in targeted
cancer therapy we will further evaluate ADCs built using this
method for targeted drug delivery in tumor-bearing mice.
■ CONCLUSION
We have demonstrated that it is possible to make homogeneous
protein conjugates through the chemo- and regioselective
modification of lysine. This was achieved by using a sulfonyl
acrylate reagent that was designed to selectively target the ε-
amino group of the most reactive lysine in the presence of other
groups such as the thiols of cysteines. The basis for this
chemoselectivity is the transient hydrogen bonding of the lysine
amine with the sulfone moiety of the featured reagent occurring
in the aza-Michael addition transition state, which significantly
decreases its activation barrier and accelerates ligation by several
million-fold. This hydrogen bond activation facilitates both the
aza-Michael addition and the subsequent expulsion of the
methanesulfinate leaving group, which provides an additional
thermodynamic driving force. Such an activation mechanism
enhances the intrinsic nucleophilicity of neutral lysine residues,
enabling aza-Michael ligation even at nearly neutral pH where
the fraction of neutral, nucleophilic lysines is small. This reaction
proceeds to full conversion with only a molar equivalent of
reagent, without perturbing protein secondary structure or
impairing protein function. This reaction was deployed
successfully on five proteins of diverse structure including a
full-length IgG antibody. In all cases a specific lysine was
modified and the regiochemical outcome (i.e., which lysine was
modified) could be predicted for medium-sized proteins based
on computational determination of the pKa of each lysine
residue. The modified proteins show stability in human plasma
while preserving innate biological activity. Importantly, proteins
bearing the acrylate moiety can be further labeled in a site-specific
manner in a subsequent aza-Michael ligation with amine-
containing synthetic molecules including PEG, fluorophores,
and an anticancer drug. We demonstrate that an apoptosis
protein biomarker and a therapeutic antibody, when fluo-
rescently labeled through this operationally simple protocol, can
be used to detect apoptotic and antigen positive cells,
respectively. In addition, our enabling platform for site-selective
lysine protein modification is compatible with other conjugation
chemistries, as exemplified with the pre- or postmodification of
cysteine residues through mixed disulfide formation.
Our discovery of sulfonyl acrylate 1c and its ability to harness
the subtle reactivity differences between the many lysine residues
on native proteins is a significant advance in protein
modification. The majority of other lysine modification methods
typically result in a mixture of products, with multiple lysines
modified. In contrast, this method can provide a single lysine
modification with complete chemo- and regioselectivity. This
level of selectivity and synthetic logic in this strategy is akin to the
advances in C−H functionalization of complex molecules, where
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functional groups traditionally viewed as indistinguishable can be
modified regioselectively when the innate reactivity of the target
group is carefully matched with an appropriate reagent.69−71
Furthermore, this method of protein modification does not
require genetic engineering and can be carried out on native
protein structures with complete selectivity. This is a critical
advance because it means that no sequence perturbations are
required that could lead to impaired activity.
We are currently exploring extensions of this approach to
conjugate two different drugs onto an antibody. This could be
done at lysine, for instance, with one drug linked as an ester of the
sulfonyl acrylate reagent and another drug attached through aza-
Michael addition to the alkene generated after conjugation.
Alternatively, the lysine conjugation here could be used in
combination with other bioconjugation chemistries directed at
different functionalities. The simplicity of the protocol,
availability of synthetic reagents, and direct applicability to
wild-type protein sequence bode well for routinely accessing site-
selectively modified proteins for basic biology and therapeutic
applications.
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